Most cited papers from Currax Pharmaceuticals (United States)

The most cited paper from Currax Pharmaceuticals (United States) is "The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy" (Carel Wynand le Roux, Nadège Fils‐Aimé, Fernando Camacho et al., 2022), with 30 citations. Next come "Extended‐release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials" (27) and "Psychiatric Safety and Weight Loss Efficacy of Naltrexone/bupropion as Add-on to Antidepressant Therapy in Patients with Obesity or Overweight" (23).

Showing 6 of 6 papers. Every paper is listed.

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.